295 related articles for article (PubMed ID: 12466244)
1. Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle.
Walch L; Norel X; Bäck M; Gascard JP; Dahlén SE; Brink C
Br J Pharmacol; 2002 Dec; 137(8):1339-45. PubMed ID: 12466244
[TBL] [Abstract][Full Text] [Related]
2. An alternative pathway for metabolism of leukotriene D(4): effects on contractions to cysteinyl-leukotrienes in the guinea-pig trachea.
Bäck M; Kumlin M; Cotgreave IA; Dahlén SE
Br J Pharmacol; 2001 Aug; 133(7):1134-44. PubMed ID: 11487525
[TBL] [Abstract][Full Text] [Related]
3. A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma.
Ravasi S; Capra V; Mezzetti M; Nicosia S; Rovati GE
Mol Pharmacol; 2000 Jun; 57(6):1182-9. PubMed ID: 10825389
[TBL] [Abstract][Full Text] [Related]
4. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.
Jonsson EW
Acta Physiol Scand Suppl; 1998 Mar; 641():1-55. PubMed ID: 9597121
[TBL] [Abstract][Full Text] [Related]
5. Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes.
Bäck M; Norel X; Walch L; Gascard J; Mazmanian G; Dahlén S; Brink C
Eur J Pharmacol; 2000 Aug; 401(3):381-8. PubMed ID: 10936497
[TBL] [Abstract][Full Text] [Related]
6. Prostacyclin modulation of contractions of the human pulmonary artery by cysteinyl-leukotrienes.
Bäck M; Norel X; Walch L; Gascard J; de Montpreville V; Dahlén S; Brink C
Eur J Pharmacol; 2000 Aug; 401(3):389-95. PubMed ID: 10936498
[TBL] [Abstract][Full Text] [Related]
7. Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle.
Bäck M
Acta Physiol Scand Suppl; 2002 Feb; 648():1-55. PubMed ID: 11913222
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the human cysteinyl leukotriene 2 receptor.
Heise CE; O'Dowd BF; Figueroa DJ; Sawyer N; Nguyen T; Im DS; Stocco R; Bellefeuille JN; Abramovitz M; Cheng R; Williams DL; Zeng Z; Liu Q; Ma L; Clements MK; Coulombe N; Liu Y; Austin CP; George SR; O'Neill GP; Metters KM; Lynch KR; Evans JF
J Biol Chem; 2000 Sep; 275(39):30531-6. PubMed ID: 10851239
[TBL] [Abstract][Full Text] [Related]
9. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
Trandafir CC; Nishihashi T; Ji X; Wang A; Kurahashi K
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1027-33. PubMed ID: 16445567
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma.
Ravasi S; Capra V; Panigalli T; Rovati GE; Nicosia S
Biochem Pharmacol; 2002 Apr; 63(8):1537-46. PubMed ID: 11996896
[TBL] [Abstract][Full Text] [Related]
11. The cysteinyl-leukotriene receptor antagonist BAY u9773 is a competitive antagonist of leukotriene C4 in the guinea-pig ileum.
Bäck M; Jonsson EW; Dahlén SE
Eur J Pharmacol; 1996 Dec; 317(1):107-13. PubMed ID: 8982726
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells.
Kamohara M; Takasaki J; Matsumoto M; Matsumoto Si ; Saito T; Soga T; Matsushime H; Furuichi K
Biochem Biophys Res Commun; 2001 Oct; 287(5):1088-92. PubMed ID: 11587533
[TBL] [Abstract][Full Text] [Related]
13. Differential signaling defects associated with the M201V polymorphism in the cysteinyl leukotriene type 2 receptor.
Brochu-Bourque A; Véronneau S; Rola-Pleszczynski M; Stankova J
J Pharmacol Exp Ther; 2011 Feb; 336(2):431-9. PubMed ID: 20966037
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
Nothacker HP; Wang Z; Zhu Y; Reinscheid RK; Lin SH; Civelli O
Mol Pharmacol; 2000 Dec; 58(6):1601-8. PubMed ID: 11093801
[TBL] [Abstract][Full Text] [Related]
15. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors.
Maekawa A; Kanaoka Y; Xing W; Austen KF
Proc Natl Acad Sci U S A; 2008 Oct; 105(43):16695-700. PubMed ID: 18931305
[TBL] [Abstract][Full Text] [Related]
16. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes.
Tudhope SR; Cuthbert NJ; Abram TS; Jennings MA; Maxey RJ; Thompson AM; Norman P; Gardiner PJ
Eur J Pharmacol; 1994 Nov; 264(3):317-23. PubMed ID: 7698171
[TBL] [Abstract][Full Text] [Related]
17. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
Takasaki J; Kamohara M; Matsumoto M; Saito T; Sugimoto T; Ohishi T; Ishii H; Ota T; Nishikawa T; Kawai Y; Masuho Y; Isogai T; Suzuki Y; Sugano S; Furuichi K
Biochem Biophys Res Commun; 2000 Aug; 274(2):316-22. PubMed ID: 10913337
[TBL] [Abstract][Full Text] [Related]
18. Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT₂) agonist, N-methyl-leukotriene C₄, in calcium reporter and β arrestin assays.
Yan D; Stocco R; Sawyer N; Nesheim ME; Abramovitz M; Funk CD
Mol Pharmacol; 2011 Feb; 79(2):270-8. PubMed ID: 21078884
[TBL] [Abstract][Full Text] [Related]
19. Receptor preferences of cysteinyl-leukotrienes in the guinea pig lung parenchyma.
Sakata K; Bäck M
Eur J Pharmacol; 2002 Feb; 436(1-2):119-26. PubMed ID: 11834255
[TBL] [Abstract][Full Text] [Related]
20. The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells.
Mazzetti L; Franchi-Micheli S; Nistri S; Quattrone S; Simone R; Ciuffi M; Zilletti L; Failli P
Br J Pharmacol; 2003 Feb; 138(4):707-15. PubMed ID: 12598425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
